Rare Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults, adults under legal guardianship, or minors with permission from their legal guardian, where a DNA sample or frozen blood tube is already stored in a molecular genetics laboratory.
- People being investigated for a condition involving intellectual and developmental difficulties, where the person is either between 0 and 5 years old with serious delays in movement, language, and/or social development, or aged 6 and above with confirmed intellectual and developmental difficulties based on specialist testing, and where these are accompanied by minor physical features or organ differences.
- People being investigated for albinism, where at least two of the following are present: underdevelopment of a part of the eye called the fovea, reduced pigment in the retina, light passing through the iris, crossed visual pathways in the brain, involuntary eye movement (nystagmus), or reduced pigment in the skin or hair.
- People whose previous genetic testing (such as a gene panel, exome, or genome test) either did not find a cause, or found only one copy of a likely disease-causing change in a gene linked to a condition that requires two copies to cause illness (confirm with trial site).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who declined to take part in research studies at the time they gave written consent for their genetic testing as part of their medical care.
- People who have expressed objection after receiving information about the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Julien VAN-GILS, MD, CHU Bordeaux - Hôpital Pellegrin
Phone: +335 57 82 16 32
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Methylation anomalies
Can't join this trial?
Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.